Falls Sie nur an einem bestimmten Exempar interessiert sind, können Sie aus der folgenden Liste jenes wählen, an dem Sie interessiert sind:
Nur diese Ausgabe anzeigen…
Nur diese Ausgabe anzeigen…
Nur diese Ausgabe anzeigen…
Senolytics In Disease, Ageing And Longevity - 13 Angebote vergleichen
Bester Preis: Fr. 4.84 (€ 4.95)¹ (vom 28.05.2021)Senolytics in Disease, Ageing and Longevity
ISBN: 9783030449025 bzw. 3030449025, in Englisch, Springer, gebundenes Buch, neu.
prepbooks.
Language: English. Number of Pages: 263. Weight: 1.11 lbs. Publication Date: 2020-07-16. Publisher: SPRINGER NATURE. Please refer to the section BELOW (and NOT ABOVE) this line for the product details - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - Title:Senolytics In Disease, Ageing And LongevityISBN13:9783030449025ISBN10:3030449025Author:Mu?oz-Espin, Daniel (Editor), DeMaria, Marco (Editor)Description: Binding:Hardcover, HardcoverPublisher:SPRINGER NATUREPublication Date:2020-07-16Weight:1.11 lbsDimensions:Number of Pages:263Language:English , Brand New, Fixed price, Format: Hardcover, Publication Year: 2020, Language: English, EAN: 9783030449025.
Senolytics in Disease, Ageing and Longevity (2019)
ISBN: 9783030449032 bzw. 3030449033, vermutlich in Englisch, Springer Shop, neu, E-Book, elektronischer Download.
This book offers comprehensive information on the new and rapidly evolving science of identifying and targeting senescent cells, and on the exciting prospect of new diagnostic and therapeutic opportunities for stopping, and even reversing, the progression of disease and the deterioration of the human body due to ageing. According to recent United Nations data, by 2050 one in six people worldwide will be older than age 65, with peaks rising to one in four people in Europe and North America. Remarkably, the number of persons aged 80 years or older is expected to triple, from 143 million in 2019 to 426 million in 2050. First documented in the 1960s, the concept of cellular senescence as an underlying cause of ageing has been established in the course of the last decade. Using genetically engineered mouse models, researchers have demonstrated that the selective elimination of senescent cells can block and even reverse a number of age-related dysfunctions and pathologies, promoting both better health and longer life in the elderly. These include cardiovascular diseases; neurological disorders; type 1 and type 2 diabetes; inflammatory diseases; fibrosis; geriatric syndromes; chronic diseases resulting in organ dysfunction; the integrity of the musculoskeletal system; and cancer. Some senolytic agents have already progressed into trials. These include UBX0101 for the treatment of osteoarthritis (now in phase II), a cocktail of dasatinib and quercetin for the management of idiopathic pulmonary fibrosis and chronic kidney disease, and ABT-263 in combination with senescence-inducing chemotherapies for the treatment of advanced solid tumours. In addition, the book discusses pathways to early phase clinical trials and translational approaches in medicine and ageing, highlighting new opportunities as well as current limitations, challenges and alternatives. Given its scope, it will benefit a broad audience of advanced educators, researchers, graduate students and practitioners. eBook.
Senolytics in Disease, Ageing and Longevity (2019)
ISBN: 9783030449056 bzw. 303044905X, vermutlich in Englisch, Springer Shop, Taschenbuch, neu.
This book offers comprehensive information on the new and rapidly evolving science of identifying and targeting senescent cells, and on the exciting prospect of new diagnostic and therapeutic opportunities for stopping, and even reversing, the progression of disease and the deterioration of the human body due to ageing. According to recent United Nations data, by 2050 one in six people worldwide will be older than age 65, with peaks rising to one in four people in Europe and North America. Remarkably, the number of persons aged 80 years or older is expected to triple, from 143 million in 2019 to 426 million in 2050. First documented in the 1960s, the concept of cellular senescence as an underlying cause of ageing has been established in the course of the last decade. Using genetically engineered mouse models, researchers have demonstrated that the selective elimination of senescent cells can block and even reverse a number of age-related dysfunctions and pathologies, promoting both better health and longer life in the elderly. These include cardiovascular diseases; neurological disorders; type 1 and type 2 diabetes; inflammatory diseases; fibrosis; geriatric syndromes; chronic diseases resulting in organ dysfunction; the integrity of the musculoskeletal system; and cancer. Some senolytic agents have already progressed into trials. These include UBX0101 for the treatment of osteoarthritis (now in phase II), a cocktail of dasatinib and quercetin for the management of idiopathic pulmonary fibrosis and chronic kidney disease, and ABT-263 in combination with senescence-inducing chemotherapies for the treatment of advanced solid tumours. In addition, the book discusses pathways to early phase clinical trials and translational approaches in medicine and ageing, highlighting new opportunities as well as current limitations, challenges and alternatives. Given its scope, it will benefit a broad audience of advanced educators, researchers, graduate students and practitioners. Soft cover.
Senolytics in Disease, Ageing and Longevity (2019)
ISBN: 9783030449025 bzw. 3030449025, vermutlich in Englisch, Springer Shop, gebundenes Buch, neu.
This book offers comprehensive information on the new and rapidly evolving science of identifying and targeting senescent cells, and on the exciting prospect of new diagnostic and therapeutic opportunities for stopping, and even reversing, the progression of disease and the deterioration of the human body due to ageing. According to recent United Nations data, by 2050 one in six people worldwide will be older than age 65, with peaks rising to one in four people in Europe and North America. Remarkably, the number of persons aged 80 years or older is expected to triple, from 143 million in 2019 to 426 million in 2050. First documented in the 1960s, the concept of cellular senescence as an underlying cause of ageing has been established in the course of the last decade. Using genetically engineered mouse models, researchers have demonstrated that the selective elimination of senescent cells can block and even reverse a number of age-related dysfunctions and pathologies, promoting both better health and longer life in the elderly. These include cardiovascular diseases; neurological disorders; type 1 and type 2 diabetes; inflammatory diseases; fibrosis; geriatric syndromes; chronic diseases resulting in organ dysfunction; the integrity of the musculoskeletal system; and cancer. Some senolytic agents have already progressed into trials. These include UBX0101 for the treatment of osteoarthritis (now in phase II), a cocktail of dasatinib and quercetin for the management of idiopathic pulmonary fibrosis and chronic kidney disease, and ABT-263 in combination with senescence-inducing chemotherapies for the treatment of advanced solid tumours. In addition, the book discusses pathways to early phase clinical trials and translational approaches in medicine and ageing, highlighting new opportunities as well as current limitations, challenges and alternatives. Given its scope, it will benefit a broad audience of advanced educators, researchers, graduate students and practitioners. Hard cover.
Senolytics in Disease, Ageing and Longevity (2017)
ISBN: 9783030449025 bzw. 3030449025, vermutlich in Englisch, Springer, Taschenbuch, neu, Nachdruck.
PRINT ON DEMAND Book; New; Publication Year 2017; Fast Shipping from the UK.
Senolytics in Disease Ageing and Longevity (2020)
ISBN: 303044905X bzw. 9783030449056, vermutlich in Englisch, Springer International Publishing, Taschenbuch, neu.
Senolytics in Disease Ageing and Longevity
ISBN: 3030449025 bzw. 9783030449025, vermutlich in Englisch, Springer International Publishing, gebundenes Buch, neu.
Senolytics in Disease, Ageing and Longevity Daniel Muñoz-Espin Editor
ISBN: 9783030449025 bzw. 3030449025, vermutlich in Englisch, Springer International Publishing, gebundenes Buch, neu.
Senolytics in Disease Ageing and Longevity,Daniel Mu oz Espin.